Get cash from your website. Sign up as affiliate
Showing posts with label Patent. Show all posts
Showing posts with label Patent. Show all posts

Friday, November 6, 2009

Thoughts on Philippine IPR Rights Week

world intellectual property organizationImage by mk30 via Flickr
Intellectual Property Office of the Philippines (IPOPhil)
What Is There To Celebrate About Intellectual Property ?
By Atty. Elpidio Peria

The Intellectual Property Office of the Philippines (IPOPhil) celebrated Intellectual Property Rights (IPR) Week this last week of October, ostensibly as a mandate of Presidential Proclamation 79 (1992), which, as pointed out by IPOPhil Director General Cristobal, is an expression of the fundamental policy that “recognition and adequate protection of the rights of inventors, authors and trademarks owners would enhance the economic environment needed to attract foreign investments.”
First off, is there evidence worldwide that increasing recognition and protection of the rights of inventors, authors and trademark owners would attract foreign investments?

The answer is not as straightforward as it seems. Ha-Joon Chang of Cambridge University asserts there is little evidence that protection of IPRs plays any role in foreign direct investment (FDI) decisions. Indeed, according to him, Switzerland’s experience suggests the opposite: the absence of patent laws made the country attractive to foreign investors. Much the same has been shown for historical flows of FDI to Canada and Italy and he even cites some analysts like Vaitsos who also noted that patents are often a substitute (and not a prerequisite) for FDI.

More recently, however, Keith Maskus of the University of Colorado in a 2000 study said that “while there are indications that strengthening IPRs can be an effective incentive for inward foreign direct investment, it is only a component of a broader set of factors”.

He noted that there are complementarities among IPRs, market liberalization and deregulation, technology development policies and competition regimes which lead to complicated trade-offs for various market participants.

He also noted data problems in analyzing the relationship between IPRs and foreign direct investment that it might be useful to study these further rather than to state uncritically that there is such correlation. These problems are : one, data on international FDI flows remain scarce; two, there are inherent measurement problems as it is difficult to capture the economic incentives generated by an IPR system, as they form part of a broader business framework which may have variable impacts in different situations, and three, current econometric models are inadequate in delving deeply into the relationship between foreign direct investment and IPRs.

In a 2004 study, Rod Falvey, Neil Foster and David Greenaway of the University of Nottingham and University of Vienna, reviewed 80 countries including the Philippines, to assess the impact of IPR protection on economic growth. They found that for low and high income countries stronger IPR protection significantly improves growth but for middle income countries no such relationship is found.

Perhaps the IPOPhil may want to ask the study authors in what category they placed the Philippines, but it can be assumed that the Philippines is one such middle income country. These study authors note that these middle income countries do not engage in innovative activities to any extent, but may well rely on imitative activities. They also say that the lack of a relationship between economic growth and IPRs may well be the result of opposing forces that cancel each other out : the positive impact of IPR protection on growth that works indirectly through trade and foreign direct investment is offset by the negative impact of IPRs that slows knowledge diffusion and discourages imitation.

That economic growth has been facilitated not because of strong IPRs may well be borne out by the economic history of the developed countries themselves as studied by Ha-Joon Chang of Cambridge University. According to Chang, Switzerland introduced a patent law that protected mechanical inventions in 1888, but a comprehensive patent law was introduced only in 1907. The Netherlands first introduced a patent law in 1817, but then abolished it in 1869 because patents were seen to create a monopoly that was inconsistent with the country’s commitment to free trade and free markets. Patent law was reintroduced in the Netherlands only in 1912. Interestingly, the 19th-century economists that were most committed to free trade and free markets rejected patents because of the monopoly argument.

Ha Joon Chang continues: other industrialized countries had patent laws by the mid-19th century. But until well into the 20th century these laws fell well short of the stringent standards now demanded of developing countries through the TRIPS agreement. For instance, in the 19th century many countries granted patents to inventions that were imported from abroad, and generally did not check for originality prior to issuing a patent. Japan, Switzerland and Italy did not recognize patents on chemical and pharmaceutical substances (as opposed to the processes of creating them) until the 1970s. Canada and Spain did not recognise these types of patents until the early 1990s. Up until quite recently, India took the same approach to patents on chemical and pharmaceutical substances.

What is it about intellectual property that we are celebrating given that there is no clear link between IPRs and foreign direct investment and it is not even clear that IPRs will contribute to a country’s economic development, especially so when that country is middle-income?

Perhaps the celebration is on the part of the holders of intellectual property, as now, with the help of the IPOPhil and its drive towards enforcement of their property rights, they can be assured of a steady stream of royalties which is guaranteed income for them for the duration of the said intellectual property.

But shouldn’t the IPOPhil be concerned more about the developmental aspects of IPR, including the notion of whether it promotes the right kinds of incentives to foster creativity and innovation ?

An academic from the University of Hawaii at Manoa, Debora Halbert did a case study on Chad and Mali, two countries in Africa, to assess whether the activities of the World Intellectual Property Organization or WIPO, the United Nations body that promotes intellectual property, had been beneficial to the two countries. She found that while WIPO has contributed to institution building of the two countries, their economic, social, cultural and political development have not been substantially enhanced, notwithstanding the almost four decades of meetings and educational activities facilitated or organized by WIPO with the local authorities.
If our own IPOPhil will put emphasis on the enforcement of intellectual property rights, rather than on the developmental aspects or concerns of the greater populace, then perhaps, the Philippines may end up like the two African countries.

Take the case, for example, about the recent suit of Pfizer against UNILAB for the alleged infringement of the latter’s patent on Lipitor, an anti-cholesterol drug. This is an occasion for the newly-enacted law, the Cheap Medicines Act (Republic Act 9502) to be tested, whether its provisions on the flexibilities in the way patent law is exercised can apply in this case.

Flexibilities in the patent laws are recognized even by the World Trade Organization, to take into account a country’s level of development in the way drug patents are enforced.

This brings to mind also what the IPOPhil is supposed to do under the Cheap Medicines Act, which is to develop a Manual for Patent Examiners, which are supposed to tighten the rules on what are patentable, in order to prevent “evergreening” – a bad practice of pharmaceutical companies where they seek to extend the lifetime of existing drug patents in order to continue monopolizing a market for a particular kind of drug.

Along with the promotion of greater access to medicines with the enforcement of the above-mentioned Cheap Medicines Act, the IPOPhil has to show more efforts that it is more concerned about the broader development of the Filipino nation, culturally, economically, technologically rather than on the narrow aspects of strong enforcement of intellectual property, which only benefits the few rights holders.
If IPOPhil Director-General Cristobal really believes that more economic incentives are in order for one to really work hard for something, then does this mean that he needs more economic incentives now? If he says “yes”, then he is not working as hard as he should be and if he says “no” then it means he is not well-compensated for his efforts. Or does it mean that there are reasons for people to do what they are doing, and incentives fostered by intellectual property do not give the proper incentives ? But that last question deserves another discussion for another occasion.
Enhanced by Zemanta

Wednesday, November 4, 2009

LEGAL HEIRS

LEGAL HEIRS
certificate of the first homestead according t...Image via Wikipedia
By Beverly Caboteja

As is implicit in said Section 119 of the Public Land act, where the vendor is still living, he alone has the right of redemption, but if he had died, his widow and his legal heirs have that right.

As stated in Section 119: “Every conveyance of land acquired under the free patent or homestead provisions of the Public Land Act, when proper, shall be subject to repurchase by the applicant, his widow or legal heirs, within a period of five (5) years from the date of conveyance.”

It has been noted that the enumeration in the law as to who can effect the repurchase within a period of five years from the date of conveyance is not an exclusionary rule. It merely includes the persons qualified under the law to make repurchase, without regard to order of preference. Hence, the son and lawful heir of the homesteader can exercise the right of repurchase while the latter is still living, and a deed of assignment to that effect is valid.

Further, the term legal heir, as explained in the case of Medarcos v. Merrced (174 SCRA 599), is used in Section 119 in a generic sense. It is broad enough to cover any person who is called to the succession either by provision of a will or by operation of law. Thus, legal heirs, according to the Court, include both testate and intestate heirs depending upon whether succession is by the will of the testator or by law. Legal heirs are not necessarily compulsory heirs but they may be if the law so prescribes or reserves it for them. Nonetheless, well-settled is the rule that only the vendor has the right to redemption.

In the aforementioned case, as the decedents had left no will, the law supplanted its intention. Since the deceased couple were childless and are survived only by their nephew and nieces, the latter succeeded to the entire estate of the deceased.

Article 975 of the Civil Code states that “when children of one or more brothers or sisters of the deceased survive, they shall inherit from the latter by representation, if they survive with their uncles or aunts. But if they alone survive, they shall inherit in equal portions.”

Verily, the Court held that petitioners are legal heirs. Having been decreed under the rules on intestacy as entitled to succeed the estate of the Catain spouses due to the absence of compulsory heirs, they now step into the shoes of the decedents. They should be considered as among the legal heirs contemplated by Section 119 as entitled to redeem the property.

In sum, in any of the 3, the applicant, his widow or his legal heirs may avail of the right to repurchase but take note, that it is only the vendor who has the right of redemption.
Enhanced by Zemanta

Tuesday, November 3, 2009

PFIZER-UNILAB TIFF : It's Not About The Patents

Four nutrient agar plates growing colonies of ...Image via Wikipedia
PFIZER-UNILAB TIFF :
It's Not About The Patents, Stupid!
By Atty. Elpidio Peria

The case filed by Pfizer Philippines, Inc. against the Filipino pharmaceutical firm United Laboratories, Inc. (UNILAB) is not mainly about the patent that was issued by the Intellectual Property Office of the Philippines; rather, it is about maintaining worldwide market control over the product, which is a cash-cow for the company, earning it around US$ 12.7 billion worldwide in 2007, making the drug its best-selling drug ever in its corporate history, and the number one best-selling drug in the world.

Policy-makers and the general public should take note, however, that to maintain its good standing in the US market, Pfizer as reported by the Los Angeles Times last 15 May 2009, had been giving Lipitor away, for free, including viagra, to Americans who have lost their jobs and health insurance from the US recession since January 1 of this year, for up to a year.

The only requirement for this freebie is that those jobless have been on the Pfizer drug for three months or more.

This marketing and public relations ploy stands in contrast to the other marketing methods that were found to be fraudulent by the US FDA itself, especially when on September 2, 2009, it was reported by Reuters to have agreed to pay $2.3 billion to resolve criminal and civil allegations that it illegally promoted several of its drugs beyond U.S. Food and Drug Administration-approved uses and dosages.

In the case of Lipitor as with its other drugs, Pfizer was found to have given kickbacks to providers to have such medicine prescribed.

Pfizer will do anything to maintain its market dominance over the product.

But the bigger prize for now seems to be the potential of statin drugs like Lipitor to combat swine flu. The New York Times reported on 29 October 2009 that people who took Lipitor when they caught flu and had to be hospitalized, were twice as likely to survive than those who were not on such medicines.

It was also reported that a federal study is underway to test these occurrences and doctors are optimistic because previous studies have shown that statins improve survival from infectious diseases.

According to the World Health Organization (WHO) website on the AH1NI1 virus, as of 25 October 2009, there have been more than 440,000 laboratory confirmed cases of pandemic influenza H1N1 2009 and over 5700 deaths reported to WHO worldwide.

The WHO figures appear with a disclaimer that since countries are no longer required to test and report individual cases, the number of cases reported actually understates the real number of cases.

Given this potential for a new market for Lipitor, Pfizer is just acting like a typical monopolist seeking to maintain its dominance on its best-selling drug, even extending its monopoly power to new uses of that same drug.

What Pfizer may want to prove in its suit against UNILAB is its ability to have its patent extended whenever there are new uses of that same drug.

Pfizer will then use this legal principle to apply for a new set of patents on this same drug, but this time with a new application of Lipitor, most probably, swine flu, or with any other disease or pandemic that may come along in the future, which the drug can treat.

When that happens, then Pfizer may have succeeded in 'evergreening' its patent.

'Ever-greening' consists of the patenting of minor changes to or versions of existing products (e. g. formulations, dosage forms, polymorphs, salts, etc.) in order to extend the life of the original patent over an active ingredient.

Whether Pfizer will succeed in getting this legal principle upheld is an interesting matter that will test the effectivity of the new law, the Cheap Medicines Act or Republic Act 9502 in dealing with these issues.

The said law states what may no longer be patentable in the case of inventions relating to drugs and medicines :
a) the mere discovery of a new form or new property of a known substance which does not result in the enhancement of the known efficacy of that substance,
b) the mere discovery of any new property or new use for a known substance,
c) the mere use of a known process unless such known process results in a new product that employs at least one new reactant.

To a non-lawyer, and even lawyers with no background in patent law, all these legal terms boil down to a requirement that for a new chemical substance to be patentable, it must be shown to have an enhanced efficacy.

What efficacy means however is not yet clear, as the implementing regulations of the Cheap Medicines Act on this matter has not yet come out.

The Cheap Medicines Act tasks the Intellectual Property Office of the Philippines (IPO) the duty to develop the criteria for determining what efficacy means, which shall be embodied in the Manual for Substantive Examination Procedure (MSEP).

The Manual is what will guide patent examiners on whether to grant or deny patent applications before the IPO.

But so far, the IPO has not come out with information even on its website what it is doing to develop this Manual as the current Manual on its website does not contain any references to the Cheap Medicines Act.
oOo
Enhanced by Zemanta

Sunday, October 25, 2009

Blog on Philippine laws and jurisprudence

Supreme Court BuildingImage by deltaMike via Flickr
On lazy weekends, we hope we can publish respectable blogs on Philippine laws and latest decisions by the Supreme Court.
This is initial posting, and hopefully more to come.
Welcome!

Philippine Law Blog
Enhanced by Zemanta
Get cash from your website. Sign up as affiliate.
Buy and Sell Philippines : Sulit.com.ph
Join My Community at MyBloglog!
Add url

Top Philippine sites